The effect of NM-monomethyl L-arginine (LNMMA), an analogue of L-arginine (a proposed precursor of endothelium-derived relaxing factor [EDRF]), on EDRF release from bovine pulmonary artery endothelial cells was investigated using endothelial cell-vascular smooth muscle cocultures and a superfused column containing endothelial cells grown on microcarrier beads. Cocultures were stimulated with control buffer, ATP, bradykinin, melittin, A23187, or nitroprusside in the presence and absence of varying concentrations of LNMMA (30-300 pM). LNMMA caused significant, concentration-dependent decreases in cyclic GMP accumulation in response to the endothelium-dependent dilators bradykinin, ATP, melittin, and A23187 but had no effect on control or nitroprusside-stimulated cocultures. The inhibitory effect of LNMMA on cyclic GMP accumulation was partially reversed by treatment with L-arginine, but was unaffected by D-arginine. To determine the specific site of action of LNMMA, endothelial cells on microcarrier beads were placed in a column and superfused with buffer. The effluent from the column was collected in 30-second (1.5-ml) fractions into 2-cm2 monolayer wells of vascular smooth muscle cells before and after addition of agonists (bradykinin, A23187) to the column inflow. The cyclic GMP content of each well of smooth muscle cells was determined as an index of EDRF activity. LNMMA superfused through the endothelial cell column inhibited cyclic GMP accumulation in vascular smooth muscle cells induced by bradykinin and A23187. LNMMA introduced into the effluent from the endothelial cell column had no effect on smooth muscle cyclic GMP levels. We conclude that LNMMA is an effective, specific inhibitor of EDRF production or release, and its action is specific to the endothelial cell. (Circulation Research 1990;67:979-985) En ndothelium-derived relaxing factor (EDRF) has been characterized pharmacologically as nitric oxide (NO) or a nitrogen oxiderelated compound.1-4 Considerable evidence suggests that endothelial cells synthesize NO from the 
LNMMA caused significant, concentration-dependent decreases in cyclic GMP accumulation in response to the endothelium-dependent dilators bradykinin, ATP, melittin, and A23187 but had no effect on control or nitroprusside-stimulated cocultures. The inhibitory effect of LNMMA on cyclic GMP accumulation was partially reversed by treatment with L-arginine, but was unaffected by D-arginine. To determine the specific site of action of LNMMA, endothelial cells on microcarrier beads were placed in a column and superfused with buffer. The effluent from the column was collected in 30-second (1.5-ml) fractions into 2-cm2 monolayer wells of vascular smooth muscle cells before and after addition of agonists (bradykinin, A23187) to the column inflow. The cyclic GMP content of each well of smooth muscle cells was determined as an index of EDRF activity. LNMMA superfused through the endothelial cell column inhibited cyclic GMP accumulation in vascular smooth muscle cells induced by bradykinin and A23187. LNMMA introduced into the effluent from the endothelial cell column had no effect on smooth muscle cyclic GMP levels. We conclude that LNMMA is an effective, specific inhibitor of EDRF production or release, and its action is specific to the endothelial cell. M), sodium nitroprusside (1 x 10 6 M), and buffer as a blank control. These concentrations of agonist were shown previously to maximally stimulate cyclic GMP accumulation.14,16 Each of these agonists was studied in the presence and absence of three concentrations of LNMMA (3 x 10-5, 1 x 104, and 3 x 104M). LNMMA was added to culture wells 5 minutes before agonist stimulation. In some experiments, L-arginine (3 x 10-4 M) or D-arginine (3 x 10`M) was added to culture wells 5 minutes before the addition of LNMMA (1 X 10-4 M). Forty seconds after the addition of agonists (shown in preliminary studies to be the optimal time for detecting cyclic GMP changes under the current experimental conditions), the media in the culture well was aspirated, and 0.5 ml of 0.1N HCl was added to each well to extract cyclic GMP.
Column Transfer Experiments
A cell column for transfer of EDRF was prepared by placing endothelial cells grown on microcarrier beads (0.12 g, or approximately 4x 10`-cells) into the barrel of a 5-ml syringe with 100-,um nylon mesh fixed in its tip to prevent the beads from washing out. The cell column was superfused with oxygenated (95% 02-5% C02) modified Krebs' buffer at 3 ml/min and maintained at 370 C by a peristaltic pump. The column effluent was assayed for EDRF by collecting 1.5-ml (30-second) fractions into culture wells (2cm2) containing confluent vascular smooth muscle cells. Fifteen seconds after collection of each fraction, the buffer from that well was aspirated and replaced with 0.5 ml of 0.1N HCl to extract cyclic GMP. The cell columns were stimulated to release EDRF by infusing bradykinin (1x 10 8 M) or A23187 (1x 10-6 M) into the inflow to the cell column for 30 seconds. The effluent from the cell column was collected using vascular smooth muscle culture wells like a fraction collector (30-second fractions) for a total of 5 minutes beginning 30 seconds before agonist infusion. In some experiments, LNMMA (lX 10-4 M) was superfused through the column of endothelial cells, while in other experiments, LNMMA (1x 10-4 M) was introduced into the effluent exiting the column so that only the smooth muscle cells were exposed to the compound. In both cases, the LNMMA infusion was begun 2 minutes before agonist stimulation of the endothelial cell column and continued through the duration of the experiment. Radioimmunoassay of Cyclic GMP Vascular smooth muscle cyclic GMP concentrations were determined by radioimmunoassay of acetylated HCI extracts by the method of Harper and Brooker,17 as modified by Patel and Linden18 using an automated radioimmunoassay.
Drugs and Chemicals
Bradykinin, melittin, ATP, A23187, sodium nitroprusside, L-arginine, D-arginine, and isobutylmethyl xanthine were obtained from Sigma Chemical Co., St. Louis. LNMMA was obtained from Calbiochem Corp., La Jolla, Calif. All drugs were prepared in distilled deionized water at 100 times their final concentration, except for A23187 and isobutylmethyl xanthine. A23187 was dissolved in dimethyl sulfoxide and diluted into buffer immediately before use. The final concentration of dimethyl sulfoxide did not exceed 0.1%, a concentration that had no effect on cyclic GMP in preliminary coculture and column experiments. A stock solution of isobutylmethyl xanthine was prepared in 2N NaOH and diluted into buffer before use. Penicillin and streptomycin were obtained from GIBCO Laboratories, Grand Island, N.Y.
Statistical Analysis
Comparisons between groups were made using oneway analysis of variance followed by Dunnett's test or the Newman-Keuls test when significant differences were present. Values of p<0.05 were accepted as significant. Values are expressed as mean±SEM. The amount of tone detected in vascular segments or * * * * * * * * reflected by blood pressure, therefore, is the end result of several additive and opposing events. For A231871 these reasons, cyclic GMP accumulation is a much .________________________________ .more specific indicator of the production of EDRF, -1 0 1 2 3 4 5 which presently is the only known endogenous acti-TIME, min vator of soluble guanylate cyclase in vascular smooth muscle. The results of this study indicated that 8. Endothelial cell column to vascular smooth LNMMA specifically inhibits the production of an endothelium-derived relaxing factor transfer experi-EDRF that acts on guanylate cyclase. The ability to NG-Monomethyl L-arginine (LNMMA, 1 xlO-M) isolate the endothelium from the vascular smooth ussed above or below the column of endothelial cells.
muscle by cell culture has allowed us to determine a2terials and Methods"for details ofprotocol. A23187, that the specific site (cell type) at which LNMMA cium ionophore A23187 (1xlO-6 M). Data are exerts its action is the endothelium.
ed as mean+±SEM; n=3 for each data point.
The present study demonstrates that in cocultures cantly different from control (p<0.05).
LNMMA inhibits cyclic GMP accumulation stimulated by the endothelium-dependent dilators bradyuine or other basic amino acids. Subsequently, kinin, melittin, ATP, and the calcium ionophore A, an analogue of L-arginine, was reported to A23187. LNMMA also inhibited basal EDRF release )ecific inhibitor of EDRF formation.'0 LNMMA as measured by cyclic GMP accumulation in control, ed in a dose-dependent manner the endotheliunstimulated cocultures. LNMMA had no effect, pendent vascular relaxations induced by acetylhowever, on cyclic GMP accumulation induced by , the calcium ionophore A23187, and substance the endothelium-independent vasodilator sodium hout affecting the endothelium-independent nitroprusside. The specificity of LNMMA for L--ion of rabbit aortic rings by nitroglycerin or arginine was suggested by the fact that L-arginine i nitroprusside. LNMMA ide anion from the endothelium. A more likely explanation is derived from the methodology of their study in which phenylephrine was used to precontract all rat aortic rings studied. It is well established that phenylephrine stimulates the release of EDRF from the endothelium, which attenuates its direct contractile effect on vascular smooth muscle. 35 The observed endothelium-dependent reversal by LNMMA of endothelium-independent vasodilation could thus be explained by LNMMA inhibition of EDRF production by phenylephrine. Indeed, we have observed that the addition of LNMMA (1 x 10`4 M) to rat aortic rings precontracted with phenylephrine (EC50) causes a 30% increase in developed tone when the endothelium is intact but has no effect when the endothelium has been removed (R.A. Johns, unpublished observation).
The results of our study also support the suggestion that endothelial cells release some EDRF even under basal conditions. Adding endothelial cells to smooth muscle cells increases basal cyclic GMP production. This effect is not attributable to cyclic GMP in endothelial cells and thus most likely is due to the basal release of EDRF. Consistent with this idea is the observation that LNMMA inhibits basal cyclic GMP accumulation in cocultures.
The scientific community is in agreement that the activation of soluble guanylate cyclase probably is mediated via a free radical (NO or nitrosothiol) that interacts with the heme moiety of the cyclase. The complexing of heme results in activation of guanylate cyclase. At issue really is the source of the NO: Is the NO generated within the smooth muscle target cells in response to an endothelium-derived external signal, or is NO released by the endothelium in quantities that are sufficient to ensure diffusion and accumulation by smooth muscle?
